Compositions and Methods for Treatment and Prevention of Cardiovascular Disease

• US 20100234442A1
• Filed: 03/12/2010
• Published: 09/16/2010
• Est. Priority Date: 03/13/2009
• Status: Abandoned Application

• Current Assignee: Nucitec S.A. de C.V.
• Original Assignee: Nucitec S.A. de C.V.
• Inventors: Rosado Loria, Jorge Luis, Duarte-Vazquez, Miguel Angel
• Application Number:
  US12/723,252
• Publication Number:
  US 20100234442A1
• Time in Patent Office: Days
• US Class Current: 514/423
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/616 by carboxylic acids, e.g. acetylsalicylic acid
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.

Claims

1. A pharmaceutical composition for the treatment of a cardiovascular disease in a mammal, comprising a therapeutically effective amount of each of at least one cholesterol lowering agent, at least one angiotensin converting enzyme inhibitor and at least one antiplatelet agent.

3. The pharmaceutical composition of claim 1, wherein said cholesterol lowering agent is simvastatin.

4. The pharmaceutical composition of claim 3, wherein said composition comprises from about 5 mg to about 140 mg of simvastatin.

5. The pharmaceutical composition of claim 3, wherein said composition comprises from about 20 mg to about 80 mg of simvastatin.

6. The pharmaceutical composition of claim 3, wherein said composition comprises about 20 mg of simvastatin.

7. The pharmaceutical composition of claim 1, wherein said angiotensin converting enzyme inhibitor is enalapril.

8. The pharmaceutical composition of claim 7, wherein said composition comprises from about 1 mg to about 80 mg of enalapril.

9. The pharmaceutical composition of claim 7, wherein said composition comprises from about 10 mg to about 60 mg of enalapril.

10. The pharmaceutical composition of claim 7, wherein said composition comprises about 10 mg of enalapril.

11. The pharmaceutical composition of claim 1, wherein said antiplatelet agent is acetylsalicylic acid.

12. The pharmaceutical composition of claim 11, wherein said composition comprises from about 20 mg to about 500 mg of acetylsalicylic acid.

13. The pharmaceutical composition of claim 11, wherein said composition comprises from about 35 mg to about 350 mg of acetylsalicylic acid.

14. The pharmaceutical composition of claim 11, wherein said composition comprises about 35 mg to about 100 mg of acetylsalicylic acid.

15. The pharmaceutical composition of claim 11, wherein said composition comprises about 75 mg of acetylsalicylic acid.

16. The pharmaceutical composition of claim 1, wherein said composition comprises simvastatin, enalapril and an antiplatelet agent.

22. The pharmaceutical composition of claim 1, wherein said composition comprises from about 10 mg to about 60 mg of enalapril, and from about 20 mg to about 80 mg of simvastatin.

23. The pharmaceutical composition of claim 1, wherein said composition comprises about 10 mg of enalapril, and about 20 mg of simvastatin.

24. The pharmaceutical composition of claim 1, wherein said composition comprises simvastatin, enalapril and acetylsalicylic acid.

25. The pharmaceutical composition of claim 24, wherein said composition comprises from about 1 mg to about 80 mg of enalapril, from about 5 mg to about 140 mg of simvastatin, and from about 20 mg to about 500 mg of acetylsalicylic acid.

33. The pharmaceutical composition of claim 1, wherein said composition comprises from about 10 mg to about 60 mg of enalapril, from about 20 mg to about 80 mg of simvastatin, and from about 35 mg to about 350 mg of acetylsalicylic acid.

35. The pharmaceutical composition of claim 1, wherein said composition comprises about 10 mg of enalapril, about 20 mg of simvastatin, and about 75 mg of acetylsalicylic acid.

36. The pharmaceutical composition of claim 1, wherein said composition is formulated for oral administration, parenteral administration or topical administration.

38. The pharmaceutical composition of claim 36, wherein said composition is in the form of a tablet, a capsule or a powder dispersible in water or a beverage.

2. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (canceled)

31. (canceled)

32. (canceled)

34. (canceled)

37. (canceled)

39. (canceled)

40. (canceled)

41. (canceled)

42. A method of treating or preventing cardiovascular disease in a mammal, comprising administering to said mammal a cardiovascular disease-treating or cardiovascular disease-preventing amount of a pharmaceutical composition comprising a cholesterol lowering agent, an angiotensin converting enzyme inhibitor, and an antiplatelet agent.

43. The method of claim 42, wherein said cardiovascular disease is hypercholesterolemia or hypertension.

44. The method of claim 42, wherein said cholesterol lowering agent is simvastatin.

45. The method of claim 44, wherein simvastatin is present in an amount from about 5 mg to about 140 mg of simvastatin.

48. The method of claim 42, wherein said angiotensin converting enzyme inhibitor is enalapril.

49. The method of claim 48, wherein enalapril is present in amount from about 1 mg to about 80 mg of enalapril.

52. The method of claim 42, wherein said antiplatelet agent is acetylsalicylic acid.

53. The method of claim 52, wherein acetylsalicylic acid is present in amount from about 20 mg to about 500 mg of acetylsalicylic acid.

57. The method of claim 42, comprising administering to said mammal said pharmaceutical composition comprising simvastatin, enalapril, and an antiplatelet agent.

63. The method of claim 42, wherein said composition comprises from about 10 mg to about 60 mg of enalapril, and from about 20 mg to about 80 mg of simvastatin.

64. The method of claim 42, wherein said composition comprises about 10 mg of enalapril, and about 20 mg of simvastatin.

65. The method of claim 42, wherein said composition comprises simvastatin, enalapril and acetylsalicylic acid.

66. The method of claim 65, wherein said composition comprises from about 1 mg to about 80 mg of enalapril, from about 5 mg to about 140 mg of simvastatin, and from about 20 mg to about 500 mg of acetylsalicylic acid.

74. The method of claim 42, wherein said composition comprises from about 10 mg to about 60 mg of enalapril, from about 20 mg to about 80 mg of simvastatin, and from about 35 mg to about 350 mg of acetylsalicylic acid.

76. The method of claim 42, wherein said composition comprises about 10 mg of enalapril, about 20 mg of simvastatin, and about 75 mg of acetylsalicylic acid.

77. The method of claim 42, wherein said composition is an aqueous solution.

78. The method of claim 42, wherein said composition is in a solid dosage foam.

79. The method of claim 42, wherein said composition is administered to said mammal orally, parenterally or topically.

81. The method of claim 42, wherein said composition is administered orally to said mammal in the form of a tablet, a capsule or a powder that is dispersed in water or a beverage.

84. The method of claim 42, wherein said composition is administered single, once daily dose.

85. The method of claim 42, wherein said mammal is a human.

46. (canceled)

47. (canceled)

50. (canceled)

51. (canceled)

54. (canceled)

55. (canceled)

56. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

67. (canceled)

68. (canceled)

69. (canceled)

70. (canceled)

71. (canceled)

72. (canceled)

73. (canceled)

75. (canceled)

80. (canceled)

82. (canceled)

83. (canceled)